Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
Testimony of John F. Crowley President and CEO,…
Chairman Griffith, Chairman Guthrie, Ranking Member DeGette, Ranking Member Pallone, and distinguished members of the subcommittee, thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO)…
Learn more
CSBA Letter to Congressional Leaders on PBM, PPRV…
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
Learn more
BIO's Comments on Advisory Committee on…
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Testimony of John F. Crowley President and CEO, BIO House Committee on Energy and Commerce Subcommittee on Health Hearing on “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain"
February 11, 2026
Chairman Griffith, Chairman Guthrie, Ranking Member DeGette, Ranking Member Pallone, and distinguished members of the subcommittee, thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO)…
CSBA Letter to Congressional Leaders on PBM, PPRV, and SBIR
December 8, 2025
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
BIO's Comments on Advisory Committee on Immunization Practices (ACIP) - December 2025
December 4, 2025
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
Testimony of BIO President & CEO John F. Crowley before the Senate Health, Education, Labor, and Pensions (HELP) Committee: “The Future of Biotech: Maintaining U.S. Competitiveness and Delivering Lifesaving Cures to Patients”
October 29, 2025
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
BIO Statement on Vaccines and Autism
September 23, 2025
Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating…
BIO's Comments to CDC’s Advisory Committee on Immunization Practices (ACIP)
September 16, 2025
Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in…
CSBA Letter to Congressional Leaders Supporting SBIR Reauthorization
August 13, 2025
Dear Majority Leader Thune, Minority Leader Schumer, Speaker Johnson, and Minority Leader Jeffries:The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory based non-profit trade associations, each of…
CSBA Letter to Congressional Leadership Supporting R&D Tax Expensing Legislation
May 29, 2025
John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s Executive Order on most favored nation:
May 12, 2025
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…
CSBA Letter to Congressional Leadership on Most Favored Nation Foreign Reference Pricing
May 8, 2025